EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Public Policy and COVID-19 Pandemic on Hepatitis C Testing and Treatment in France, 2014–2021

Cécile Brouard iD, Manon Schwager, Aude Expert, Nicolas Drewniak iD, Stella Laporal, Grégoire de Lagasnerie, Florence Lot

Viruses · 2024

DOI: 10.3390/v16050792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Cécile Brouard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Santé Publique France, The National Public Health Agency, 94415 Saint-Maurice, France. Hauptthemen laut MEDLINE: COVID-19, Antiviral Agents, Hepatitis C, Public Policy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Given the World Health Organization’s target to eliminate the hepatitis C virus (HCV) by 2030, we assessed the impact of French public policies and the COVID-19 pandemic on HCV testing and initiation of direct-antiviral agents (DAAs). Using the French National Health Data System, we identified individuals living in metropolitan France with at least one reimbursement for an anti-HCV test and those with a first delivery of DAAs between 1 January 2014 and 31 December 2021. During this period, the annual number of people tested increased each year between 3.3 (in 2015) and 9.3% (in 2021), except in 2020, with a drop of 8.3%, particularly marked in April (−55.0% compared to February 2020). A return to pre-pandemic testing levels was observed in 2021. The quarterly number of patients initiating DAAs presented an upward trend from Q1-2014 until mid-2017, with greater increases in Q1-2015, and Q1- and Q2-2017, concomitant with DAA access policies and availability of new therapies. Then, quarterly numbers decreased. A 65.5% drop occurred in April compared to February 2020. The declining DAA initiations since mid-2017, despite new measures improving access and screening efforts, could be due to the shrinking pool of patients requiring treatment and a need to increase awareness among undiagnosed infected people. Further action is needed to eliminate HCV in France.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Antiviral AgentsHepatitis CPublic PolicySARS-CoV-2HumansFranceMaleFemaleMiddle AgedPandemicsHepacivirusAgedHealth PolicyAdultMass Screening

Stichwörter der Autor:innen

COVID-19FranceFrench National Health Insurance Data System (SNDS)direct-antiviral agenthepatitis C virustestingtreatment

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Santé Publique France, The National Public Health Agency, 94415 Saint-Maurice, France.
  • Caisse Nationale de l'Assurance Maladie, 75986 Paris, France.

ORCID-Profile: Cécile Brouard, Nicolas Drewniak

Zitieren

APA

Brouard, C., Schwager, M., Expert, A., Drewniak, N., Laporal, S., de Lagasnerie, G., & Lot, F. (2024). Impact of Public Policy and COVID-19 Pandemic on Hepatitis C Testing and Treatment in France, 2014–2021. Viruses. https://doi.org/10.3390/v16050792

Vancouver

Brouard C, Schwager M, Expert A, Drewniak N, Laporal S, de Lagasnerie G, et al. Impact of Public Policy and COVID-19 Pandemic on Hepatitis C Testing and Treatment in France, 2014–2021. Viruses. 2024. doi:10.3390/v16050792

BibTeX
@article{Brouard2024,
  author = {Brouard, Cécile and Schwager, Manon and Expert, Aude and Drewniak, Nicolas and Laporal, Stella and de Lagasnerie, Grégoire and Lot, Florence},
  title = {Impact of Public Policy and COVID-19 Pandemic on Hepatitis C Testing and Treatment in France, 2014–2021},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16050792}
}
Kostenlos starten →